drugset
drugset / Trial / NCT06010537

Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

NCT06010537 ↗

Phase 0 Completed 4 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupOpen-labelDiagnostic

Summary

This is a contrast-enhanced magnetic resonance imaging (MRI) study conducted on a single-administration of polyglucose superparamagnetic iron oxide injection. Two dose groups are set up in this study, 2.5 mg/kg and 3 mg/kg, and two subjects in each group received the test drug for safety evaluation.

Timeline

Start
2021-04-28
Primary completion
2021-04-30
Completion
2021-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Polysaccharide superparamagnetic iron oxide Diagnostic / imaging agent 2.5 mg/kg Intravenous
Subject Polysaccharide superparamagnetic iron oxide Diagnostic / imaging agent 3 mg/kg Intravenous

Indications

No indication recorded.